PDCD1 and melanoma: The initial positive responses observed from the expanded cohort in the IGNYTE trial contrast a similar trial evaluating T-VEC and pembrolizumab in anti-PD-1-failed melanoma in which no confirmed responses were observed in patients with visceral lesions (NCT02965716).83